Full-Time

Application Lab Manager

Posted on 1/8/2026

Sartorius

Sartorius

5,001-10,000 employees

Laboratory instruments and bioprocess solutions

Compensation Overview

$100k - $140k/yr

Marlborough, MA, USA

In Person

Category
Lab & Research (1)
Required Skills
Inventory Management
Tableau
Salesforce
Data Analysis
Requirements
  • Bachelors degree in a relevant scientific field
  • Minimum 3+ years of experience in Laboratory Management, Product Development, or Application Specialist
  • 2 years of SFDC and Tableau
  • Excellent organizational and problem-solving abilities
  • Strong communication skills, both written and verbal
Responsibilities
  • Proactively diagnose customer technical challenges and propose customized solutions utilizing the application lab's expertise and resources
  • Oversee the maintenance and calibration of laboratory equipment to ensure optimal functionality
  • Develop and implement laboratory protocols and procedures to ensure safety and compliance with regulatory standards
  • Coordinate research projects and collaborate with cross-functional teams to achieve project goals
  • Monitor laboratory inventory and procure necessary supplies and materials
  • Analyze data and prepare reports to communicate findings to stakeholders
  • Foster a culture of continuous improvement and innovation within the laboratory
  • Ensure the laboratory is equipped with the latest technologies and methodologies to support application development
Desired Qualifications
  • Masters degree in a relevant scientific field preferred
  • Strong leadership and team management skills
  • Familiarity with laboratory safety protocols and regulatory compliance
  • Experience with fluid management technologies and systems
  • Knowledge of computational modeling and technical systems
  • Ability to work collaboratively in a fast-paced environment
  • Identification with our core values: Sustainability, Openness, Enjoyment

Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Simplify Jobs

Simplify's Take

What believers are saying

  • Order intake hit highest Q4 2025 level, book-to-bill above one.
  • Equity ratio reached 48.7% after €1B capital increase in 2024.
  • 6-10% sales growth projected for 2026 with margins above 30%.

What critics are saying

  • Trump tariffs hit German imports; US manufacturing lags by 2027.
  • Danaher's Cytiva bundling steals share from Sartorius platforms.
  • Biotech funding drop 36% in 2024 cuts customer equipment capex.

What makes Sartorius unique

  • Sartorius leads in single-use ultrafilters like Sartocon Slice 50.
  • Ann Arbor $100M Center of Excellence boosts bioanalytics innovation.
  • SIMCA-online software excels in batch process monitoring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

The Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.

Yahoo Finance
Feb 3rd, 2026
Sartorius grows revenue 7.6% to €3.5B with EBITDA margin expanding to 29.7%

Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.

Yahoo Finance
Feb 3rd, 2026
Sartorius Stedim Biotech posts 18% profit growth despite equipment softness, cuts debt ratio to 3.55

Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.

Firmenpresse
Sep 16th, 2025
Repairon secures funding for heart therapy

Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.

IT Juzi
Aug 12th, 2025
Nanotein secures $3M strategic investment

Nanotein, a cell therapy developer, has secured a $3 million strategic investment from Sartorius Stedim Biotech.

INACTIVE